Arké SMO S.A de C.V

Running trials

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

  NCT06979453· Phase 3· Source

• Recruiting

  A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

  NCT06807281· Phase 3· Source

• Active, not recruiting

  A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

  NCT06807268· Phase 3· Source

• Recruiting

  A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

  NCT06739122· Phase 3· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Source

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Source

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Source

• Recruiting

  A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

  NCT05611801· Phase 3· Source

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Source

• Recruiting

  A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis

  NCT04772079· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)2 recruiting
• Psoriasis2 recruiting
• Depression1 recruiting
• Haemophilia1 recruiting
• Lung cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

  NCT06921759· Phase 3· Source

• Completed

  Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

  NCT06354660· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

  NCT05929079· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Source

• Completed

  Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

  NCT05412004· Phase 3· Source

• Completed

  A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

  NCT05260021· Phase 3· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

  NCT04184622· Phase 3· Source

• Completed

  A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

  NCT03952559· Phase 3· Source